Table 2.
Medication use after the index stroke or TIA
| Index stroke (N = 313a) | Index TIA (N = 264a) | p-value | |
|---|---|---|---|
| Antithrombotic treatment | |||
| None | 14 (4) | 10 (4) | 0.681 |
| Antiplatelet agent | 247 (79) | 239 (91) | <0.0001 |
| Single agent (ASA or other) | 235 (75) | 230 (87) | <0.0001 |
| Double agent (ASA + other) | 12 (4) | 9 (3) | 0.786 |
| Anticoagulant agent | 51 (16) | 14 (5) | <0.0001 |
| VKA | 48 (15) | 13 (5) | <0.0001 |
| DOAC | 3 (1) | 1 (<1) | 0.629 |
| Heparin | 1 (<1) | 1 (<1) | 0.904 |
| Cytoreductive treatment | |||
| None | 32 (10) | 25 (9) | 0.762 |
| Phlebotomy | 2 (<1) | 8 (3) | 0.049 |
| Hydroxyurea | 248 (79) | 204 (77) | 0.569 |
| Alone | 224 (72) | 193 (73) | 0.680 |
| In combination | 24 (8) | 11 (4) | 0.079 |
| Anagrelide | 3 (1) | 15 (6) | 0.001 |
| Interferon | 11 (4) | 6 (2) | 0.380 |
| Ruxolitinb | 5 (2) | 3 (1) | 0.733 |
| Otherb | 12 (4) | 3 (1) | 0.063 |
Overall, 503 patients (87.2%) received either cytoreductive and antithrombotic treatments; 50 patients (8.7%) received only antithrombotic treatment (and no cytoreductive treatment), 17 patients (2.9%) received only cytoreductive treatment (and no antithrombotic treatment), and 7 patients (1.2%) received neither cytoreductive nor antithrombotic treatments
ASA acetylsalicylic acid, VKA vitamin K-antagonist, DOAC direct oral anticoagulant
aTwenty out of 597 patients (3%) have missing information on treatments after the index event
bOther cytoreductive treatment includes pipobroman, busulphan, P32